Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study

• Published in: Transplant international 2000-06, Vol.13 (S1), p.S388-S393
• Main Authors: Caillard, Sophie, Lachat, Virginie, Moulin, Bruno
• Format: Article
• Language: English
• Subjects: Age; Antiviral agents; Central nervous system; Chemotherapy; Dialysis; Epstein-Barr virus; Genotypes; Globulins; Grafting; Immunoproliferative diseases; Immunosuppressive agents; Intestine; Kidney transplantation; Lymph nodes; Mucosa; Oropharynx; Posttransplant lymphoproliferative disorders; Radiotherapy; Renal transplantation; Risk assessment; Skin; Stomach; Tumors
• ISSN: 0934-0874; 1432-2277
• DOI: 10.1111/j.1432-2277.2000.tb02067.x

New immunosuppressive therapies are currently being developed in renal transplantation and their relative risk in terms of post‐transplant lymphoproliferative disorders (PTLD) must be carefully evaluated. For this purpose, a French registry of PTLD occurring after renal transplantation was set up. Among 10000 patients presently followed up in 30 French renal transplantation centers, we prospectively identified 53 new PTLD (0.5 %) since January 1998. Patients (34 male, 19 female) ranged from 3 to 72 years (mean age: 46 years), and the median time between grafting and diagnosis of PTLD was 63 months (2 months to 14 years). Ninety percent of recipients were Epstein‐Barr virus (EBV) positive before transplantation. Most patients received a quadruple sequential therapy with polyclonal anti‐lymphocyte globulin. Sites involved in PTLD were isolated lymph nodes in 13 cases, stomach or bowel in 10 cases, allograft in 14 cases, central nervous system in 6 cases, oropharynx in 4 cases, and skin or mucosa in 4 cases. Only three PTLD expressed markers of T lineage. Out of 40 studied tumors, 31 (78%) were EBV positive. Tumors were classified as polymorph in 26 cases and monomorph in 23 cases. Genotype studies in 18 PTLD showed a monoclonal pattern in 13 cases. In most patients, treatment consisted of reduction of immune suppression, 21 patients were given additional anti‐viral therapy, 13 patients had anti‐CD20, 23 patients underwent chemotherapy, and 4 patients were given cerebral radiotherapy. Five patients underwent transplantectomy. Sixteen patients (30 %) died within the 1st year and 7 patients returned to dialysis (13 %). The outcome of patients with PTLD remains poor, and the optimal approach to therapy is largely unknown. This ongoing registry is not only a national observatory but also a task force designed to improve the treatment strategy of PTLD.